10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2017 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 22, 2018) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Revenues | $ 52,546 | 52,824 | 48,851 |
| Costs and expenses: | |||
| Cost of sales | 11,240 | 12,329 | 9,648 |
| Selling, informational and administrative expenses | 14,784 | 14,837 [1] | 14,809 |
| Research and development expenses | 7,657 | 7,872 | 7,690 |
| Amortization of intangible assets | 4,758 | 4,056 | 3,728 |
| Restructuring charges and certain acquisition-related costs | 487 | 1,724 | 1,152 |
| Other (income)/deductionsnet | 1,315 | 3,655 | 2,860 |
| Income from continuing operations before provision/(benefit) for taxes on income | 12,305 | 8,351 | 8,965 [2] |
| Provision/(benefit) for taxes on income | (9,049) | 1,123 | 1,990 |
| Income from continuing operations | 21,353 | 7,229 | 6,975 |
| Discontinued operations: | |||
| Income from discontinued operationsnet of tax | (1) | 16 | 17 |
| Gain/(loss) on disposal of discontinued operationsnet of tax | 3 | 0 | (6) |
| Discontinued operationsnet of tax | 2 | 17 | 11 |
| Net income before allocation to noncontrolling interests | 21,355 | 7,246 | 6,986 |
| Less: Net income attributable to noncontrolling interests | 47 | 31 | 26 |
| Net income attributable to Pfizer Inc. | 21,308 | 7,215 | 6,960 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 3.57 | 1.18 | 1.13 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.00 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 3.57 | 1.18 | 1.13 [3] |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 3.52 | 1.17 | 1.11 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.00 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 3.52 | 1.17 | 1.11 |
| Weighted-average sharesbasic | 5,970 | 6,089 [4] | 6,176 |
| Weighted-average sharesdiluted | 6,058 | 6,159 | 6,257 |
| Cash dividends paid per common share (in dollars per share) | 1.28 | 1.20 | 1.12 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets. | |||
| [2] 2017 v. 2016The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower certain asset impairments and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in international income was primarily due to the non-recurrence of the 2016 impairment on the remeasure | |||
| [3] Amounts may not add due to rounding. | |||
| [4] 2017 shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement. | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |